TrustCore Financial Services’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$240K Hold
2,650
0.02% 248
2022
Q3
$201K Sell
2,650
-138
-5% -$11.4K 0.02% 265
2022
Q2
$236K Buy
2,788
+138
+5% +$12.1K 0.02% 243
2022
Q1
$233K Buy
2,650
+750
+39% +$64.9K 0.02% 263
2021
Q4
$166K Sell
1,900
-100
-5% -$8.3K 0.02% 268
2021
Q3
$164K Sell
2,000
-3
-0.1% -$270 0.02% 292
2021
Q2
$183K Sell
2,003
-297
-13% -$26.4K 0.02% 277
2021
Q1
$197K Buy
2,300
+241
+12% +$21.6K 0.02% 257
2020
Q4
$194K Buy
2,059
+259
+14% +$22.6K 0.02% 248
2020
Q3
$157K Hold
1,800
0.02% 253
2020
Q2
$157K Hold
1,800
0.03% 248
2020
Q1
$148K Hold
1,800
0.03% 225
2019
Q4
$170K Sell
1,800
-205
-10% -$18.4K 0.03% 233
2019
Q3
$174K Sell
2,005
-13
-0.6% -$1.17K 0.04% 220
2019
Q2
$184K Buy
2,018
+78
+4% +$6.6K 0.04% 206
2019
Q1
$167K Buy
1,940
+177
+10% +$14.2K 0.05% 169
2018
Q4
$136K Sell
1,763
-722
-29% -$56.2K 0.08% 86
2018
Q3
$192K Sell
2,485
-134
-5% -$9.91K 0.06% 156
2018
Q2
$177K Buy
2,619
+191
+8% +$13.2K 0.06% 152
2018
Q1
$176K Buy
2,428
+55
+2% +$4.19K 0.07% 143
2017
Q4
$178K Buy
+2,373
New +$179K 0.07% 142

Other funds holding NVS

TrustCore Financial Services's NVS Position: Q4 2022 in Review

TrustCore Financial Services held its Novartis (NVS) position steady in Q4 2022 at 2,650 shares worth $240K. The position accounts for 0.02% of the portfolio, ranked #248.

TrustCore Financial Services first reported a position in NVS in Q4 2017 and has held it in 21 quarters since. 1,182 funds tracked by Wall St. Rank hold NVS as of Q4 2022.

  • TrustCore Financial Services held 2,650 shares of Novartis worth $240K as of Q4 2022.
  • TrustCore Financial Services left its Novartis share count unchanged in Q4 2022.
  • Novartis made up 0.02% of TrustCore Financial Services's portfolio in Q4 2022, its #248 holding.
  • TrustCore Financial Services first reported a position in Novartis in Q4 2017 and has held it in 21 quarters since.
  • 1,182 funds tracked by Wall St. Rank held Novartis as of Q4 2022.

Based on TrustCore Financial Services's 13F filing for Q4 2022, filed 13 Feb 2023.